Update on the Clinical Management of Atrial Fibrillation: Guidelines and Beyond
Update on the Clinical Management of Atrial Fibrillation: Guidelines and Beyond
复制标题
DOI：
10.3810/pgm.2011.11.2491
复制
发表时间：
2011-11-01
影响因子：
4.2
通讯作者：
Curtis, Anne B.
中科院分区：
文献类型：
--
作者：
Curtis, Anne B.
在临床实践中，心房颤动（AF）是最常见的心律失常。随着美国人口老龄化，医生遇到的房颤患者数量将会增加。房颤管理涉及心率和节律控制策略与血栓预防的结合，考虑到治疗的副作用、患者合并症和抗凝治疗要求，这是一项复杂的工作。早期停止治疗和抗凝治疗依从性差的情况很常见，导致死亡率增加、缺血性中风风险增加 5 倍、健康相关生活质量下降以及运动能力下降。 2006 年，美国心脏病学会/美国心脏协会/欧洲心脏病学会 (ACC/AHA/ESC) 提供了 AF 患者的治疗指南。最近，ACC 基金会、AHA 和心律协会发布了这些指南的更新（201 年 1 月和 2 月 I）。本文旨在通过关注指南中反映的治疗的主要组成部分，并提供美国食品和药物管理局批准的新治疗方法的最新信息，帮助医生改善 AF 患者的管理。
In clinical practice, atrial fibrillation (AF) is the most commonly encountered arrhythmia. With the aging of the US population, the number of patients with AF that physicians encounter will increase. Atrial fibrillation management involves a combination of rate- and rhythm-control strategies with thromboprophylaxis, a complicated endeavor given side effect profiles of treatments, patient comorbidities, and anticoagulation treatment requirements. Early treatment discontinuation and poor compliance with anticoagulation treatment are frequent and result in increased mortality, a 5-fold increased risk of ischemic stroke, decreased health-related quality of life, and decreased exercise capacity. In 2006, the American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) provided guidelines for the management of patients with AF. Recently, the ACC Foundation, AHA, and Heart Rhythm Society released updates to these guidelines (January and February 201 I). This article aims to assist physicians in improving the management of patients with AF by focusing on the main components of therapy as reflected in the guidelines, and by providing an update on new US Food and Drug Administration approved treatments.